3 results about "Mammalian Embryos" patented technology

The present disclosure provides a method for promoting in vitro development of mammalian embryos, comprising the step of adding alpha-ketoglutarate in the embryo development fluid at 90-180h after in vitro fertilization. Compared with the method of adding throughout the whole embryo development, the present disclosure finds that the promotion of embryo development efficiency is more significant when alpha-ketoglutarate is added after 90 hours after fertilization (90 hours to 180 hours after fertilization).

This invention discloses a method for inducing mouse embryonic stem cells to transition to a pluripotent state using H2BC21 and its application, belonging to the fields of molecular biology and stem cell engineering technology. By constructing an interference vector targeting the H2BC21 gene, packaging it with lentivirus, and infecting mouse embryonic stem cells, the expression of the H2BC21 gene is knocked down, and embryonic stem cell lines with stable low expression of H2BC21 are obtained through screening. This invention is the first to discover that H2BC21 is a core negative regulator of mammalian embryonic stem cell pluripotency. After knocking down H2BC21, the expression of pluripotency core genes Nanog, Oct4, and Sox2 is downregulated, while the expression of pluripotency core genes Zscan4b, Usp17la, and Tmem92 is upregulated. The cells exhibit molecular characteristics similar to 2-cell phase cells, successfully achieving the transition from pluripotency to a pluripotent state.